AFP and hepatocellular carcinoma: In contrast from previous literature in patients with HCC who underwent transarterial embolization/chemoembolization-based locoregional treatment with sorafenib or sorafenib monotherapy (32, 33), the AFP level has not been investigated as a marker for predicting treatment response.